Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children

被引:0
作者
Kaplan, SL
Afghani, B
Lopez, P
Wu, EB
Fleishaker, D
Edge-Padbury, B
Naberhuis-Stehouwer, S
Bruss, JB
机构
[1] Texas Childrens Hosp, Houston, TX 77030 USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Miller Childrens Hosp, Long Beach, CA USA
[4] Hosp Univ Valle, Cali, Colombia
[5] Hosp San Juan Dios, Santiago, Chile
[6] Pharmacia Corp, Kalamazoo, MI USA
关键词
linezolid; methicillin-resistant Staphylococcus aureus; infection; pediatric;
D O I
暂无
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Infections caused by methicillin-resistant Staphylococcus aureus (MRSA) are becoming increasingly prevalent. Linezolid is effective and well-tolerated in the treatment of adults with AMSA infections. Objective. To evaluate the clinical efficacy and safety of iv/oral linezolid in children with MRSA infections. Methods. Data were obtained from two independent clinical trials. In an outpatient trial children (5 to 17 years of age) with uncomplicated skin and skin structure infections (SSSIs) were treated with linezolid or cefadroxil. In an inpatient trial hospitalized children (0 to 11 years of age) with pneumonia, bacteremia or complicated SSSI caused by resistant Gram-positive pathogens were administered iv linezolid with the option to switch to oral suspension (patients >90 days of age) or iv vancomycin. A subset of patients with MRSA infections from the two clinical trials is analyzed herein. Results. In the outpatient trial children with skin infections caused by MRSA were treated with linezolid (15 patients) and cefadroxil (10 patients). In the microbiologically evaluable population, the clinical cure rate was 92.3% in the linezolid group and 85.7% in the cefadroxil group (P = 0.64). The pathogen eradication rate for AMSA was 92.3 and 85.7% in the linezolid and cefadroxil groups, respectively (P = 0.64). There were very few adverse events or drug-related adverse events and no serious adverse events in the outpatient trial. In the inpatient trial 20 children treated with linezolid and 14 treated with vancomycin had infections caused by MRSA. In the microbiologically evaluable population, the clinical cure rate was 94.1% in the linezolid group and 90.0% in the vancomycin group (P = 0.69). Pathogen eradication rates were 88.2 and 90.0% for the linezolid and vancomycin groups, respectively (P = 0.89). Susceptibility patterns of the AMSA isolates showed distinct patterns between the outpatient and inpatient trials. In the inpatient trial fewer patients in the linezolid group had drug-related adverse events than did those in the vancomycin group (20% vs. 43%; P = 0.15). Conclusions. Intravenous/oral linezolid is effective and well-tolerated in children with MRSA infections.
引用
收藏
页码:S176 / S183
页数:8
相关论文
共 35 条
[1]  
[Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P902
[2]   Vancomycin in surgical infections due to meticillin-resistant Staphylococcus aureus with heterogeneous resistance to vancomycin [J].
Ariza, J ;
Pujol, M ;
Cabo, J ;
Peña, C ;
Fernández, N ;
Liñares, J ;
Ayats, J ;
Gudiol, F .
LANCET, 1999, 353 (9164) :1587-1588
[3]   Linezolid for the treatment of multidrug-resistant, gram-positive infections: Experience from a compassionate-use program [J].
Birmingham, MC ;
Rayner, CR ;
Meagher, AK ;
Flavin, SM ;
Batts, DH ;
Schentag, JJ .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (02) :159-168
[4]   Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections [J].
Brickner, SJ ;
Hutchinson, DK ;
Barbachyn, MR ;
Manninen, PR ;
Ulanowicz, DA ;
Garmon, SA ;
Grega, KC ;
Hendges, SK ;
Toops, DS ;
Ford, CW ;
Zurenko, GE .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (03) :673-679
[5]  
*CDC NNIS SYST, 2002, AM J INFECT CONTROL, V30, P458
[6]  
Centers for Disease Control, 2002, MMWR-MORBID MORTAL W, V51, P565
[7]  
Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P813
[8]  
Dresser LD, 1998, PHARMACOTHERAPY, V18, P456
[9]   In vitro activities of new oxazolidinone antimicrobial agents against enterococci [J].
Eliopoulos, GM ;
Wennersten, CB ;
Gold, HS ;
Moellering, RC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (07) :1745-1747
[10]   Community-acquired methicillin-resistant Staphylococcus aureus infections in South Texas children [J].
Fergie, JE ;
Purcell, K .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2001, 20 (09) :860-863